NextCell Pharma AB announced that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, respective of pre-existing HLA antibodies. NextCell has previously reported the efficacious effect of ProTrans therapy in maintaining insulin production in newly diagnosed type I diabetes patients enrolled in the ProTrans Repeat Study.

As part of the long-term follow-up study of these treated patients, the expression of anti-HLA (human leukocyte antigen) antibodies has been investigated. All cells express HLA molecules on their surface, helping the body to establish what is foreign and self. In the case of blood transfusion or tissue matching for transplantation the donor HLA pattern is matched, where possible, to the HLA pattern of the recipient.

This prevents a reaction, or rejection, by the patient upon treatment. One of the major advantages of ProTrans treatment is the lack of need to match donor cells to patients, allowing for the development of a true off-the-shelf allogeneic therapy suitable for immediate usage. Analysis of patient samples prior to treatment and post-treatment (1 month post-second infusion) with two doses of ProTrans (equivalent to exposure to ten individual cell donors) demonstrated no anti-HLA antibodies against any donor material.

NextCell will continue their long-term follow-up of these patients for a total of five years. Data to date is very promising with no serious adverse events or safety concerns.